Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2017-11-07 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于2017年累计新增借款超过上年末净资产百分之二十的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from 瑞康医药股份有限公司 regarding the cumulative new borrowings in 2017 exceeding 20% of the previous year's net assets. It provides detailed financial data about borrowings, classifications of new borrowings, and an analysis of the impact on debt repayment ability. The document references regulatory requirements related to bond issuance and disclosure but does not contain a full financial report or comprehensive financial statements. The length is short (1178 characters), and the content is focused on a specific financing update rather than a full annual or interim report. Therefore, it fits best under Capital/Financing Update (CAP).
2017-11-07 Chinese
2017年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "2017 年第三季度报告全文" which translates to "2017 Third Quarter Report Full Text." It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2017. The document includes comprehensive financial figures, analysis of changes in financial metrics, shareholder information, and management commentary on financial results. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full quarterly financial report rather than a brief announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2017
2017-10-30 Chinese
2017年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2017 Third Quarter Report" (2017 年第三季度报告正文) of 瑞康医药股份有限公司, which indicates it is a quarterly financial report. It contains detailed financial data such as assets, liabilities, income, cash flows, and shareholder information for the third quarter of 2017. The length of the document (8260 characters) and the presence of comprehensive financial statements and analysis confirm it is a substantive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2017
2017-10-30 Chinese
关于签订2017年面向合格投资者公开发行公司债券（第一期）募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement for the management of funds raised from a 2017 public issuance of corporate bonds by the company. It details the terms of the agreement between the company, a securities firm, and a bank to regulate the use and management of the raised funds. The document does not contain financial statements, audit results, or detailed financial performance data. It is a regulatory announcement about financing activities and fund management related to a bond issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short (1852 characters), and it is not merely announcing the publication of a report but providing substantive information about the financing agreement.
2017-10-24 Chinese
2017年面向合格投资者公开发行公司债券（第一期）发行结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the issuance results of a corporate bond by 瑞康医药股份有限公司 in 2017. It details the approval by the China Securities Regulatory Commission, the bond issuance scale, pricing, interest rate, and the completion date of the issuance. This type of document is an update on the company's financing activities, specifically about bond issuance. It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting result. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and focused on the issuance result, confirming it is an announcement rather than a detailed report or presentation.
2017-10-19 Chinese
2017年面向合格投资者公开发行公司债券（第一期）票面利率公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the coupon rate for a corporate bond issuance by 瑞康医药股份有限公司 in 2017. It details the approval by the China Securities Regulatory Commission, the bond issuance scale, the coupon rate determination process, and the issuance dates. The document is short (1439 characters) and focuses on the terms of a financing activity, specifically a bond issuance. It does not contain financial statements or comprehensive financial data, nor is it a full report or earnings release. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2017-10-17 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.